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Abstract 
Background: Controlled diagnostic studies have established the prevalence of cervical facet joint 
pain to range from 36% to 67% based on the criterion standard of ≥ 80% pain relief. Treatment of 
cervical facet joint pain has been described with Level II evidence of effectiveness for therapeutic 
facet joint nerve blocks and radiofrequency neurotomy and with no significant evidence for 
intraarticular injections. However, there have not been any cost effectiveness or cost utility 
analysis studies performed in managing chronic neck pain with or without headaches with cervical 
facet joint interventions.  
Study Design: Cost utility analysis based on the results of a double-blind, randomized, controlled 
trial of cervical therapeutic medial branch blocks in managing chronic neck pain.  
Objectives: To assess cost utility of therapeutic cervical medial branch blocks in managing chronic 
neck pain. 
Methods:  A randomized trial was conducted in a specialty referral private practice interventional 
pain management center in the United States. This trial assessed the clinical effectiveness of 
therapeutic cervical medial branch blocks with or without steroids for an established diagnosis of 
cervical facet joint pain by means of controlled diagnostic blocks. Cost utility analysis was 
performed with direct payment data for the procedures for a total of 120 patients over a period of 
2 years from this trial based on reimbursement rates of 2016. The payment data provided direct 
procedural costs without inclusion of drug treatments. An additional 40% was added to procedural 
costs with multiplication of a factor of 1.67 to provide estimated total costs including direct and 
indirect costs, based on highly regarded surgical literature. Outcome measures included significant 
improvement defined as at least a 50% improvement with reduction in pain and disability status 
with a combined 50% or more reduction in pain in Neck Disability Index (NDI) scores.  
Results: The results showed direct procedural costs per one-year improvement in quality adjusted 
life year (QALY) of United States Dollar (USD) of $2,552, and overall costs of USD $4,261. 
Overall, each patient on average received 5.7 ± 2.2 procedures over a period of 2 years. Average 
significant improvement per procedure was 15.6 ± 12.3 weeks and average significant 
improvement in 2 years per patient was 86.0 ± 24.6 weeks.  
Limitations: The limitations of this cost utility analysis are that data are based on a single center 
evaluation. Only costs of therapeutic interventional procedures and physician visits were included, 
with extrapolation of indirect costs.  
Conclusion: The cost utility analysis of therapeutic cervical medial branch blocks in the treatment 
of chronic neck pain non-responsive to conservative management demonstrated clinical 
effectiveness and cost utility at USD $4,261 per one year of QALY. 
Key words: Chronic neck pain, cervical facet joint pain, cervical medial branch blocks, controlled diagnostic 
blocks, cost utility analysis, cost effectiveness analysis, quality adjusted life years (QALY). 
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Introduction 
Chronic neck pain in the general population with 
or without sprain or injury is common, with annual 
estimates of prevalence of 12.1% to 71.5% with most 
estimates demonstrating an annual prevalence of 
between 30% and 50% [1, 2]. Though less prevalent 
than low back pain, neck pain is the third most 
common chronic pain condition in the US, is 
expensive, may cause persistent pain, and is the 
fourth leading cause of disability worldwide [3, 4]. 
Global burden of neck pain studies and disability 
studies [3, 4] have revealed the prevalence of chronic 
neck pain in 4.9% of the population, with a significant 
proportion suffering with chronic neck pain with high 
disability. Martin et al. [5, 6] evaluated health care 
expenditures for the treatment of back and neck 
problems in 2005 and demonstrated that these 
expenditures total approximately United States Dollar 
(USD) $86 billion, with an increase of 65% between 
1997 and 2005 with a 49% increase in the number of 
patients seeking spine-related care. In addition, 
Dieleman et al. [7], in an analysis of U.S. spending on 
personal health care from 1996 to 2013, showed that 
low back and neck pain accounted for the third 
highest amount of health care spending in the US, 
with an estimated USD $87.6 billion in 2013. They also 
demonstrated that spending on low back and neck 
pain along with diabetes mellitus increased the most 
over the 18 years, by an estimated USD $57.2 billion 
and $64.4 billion, respectively. Multiple diagnostic 
and therapeutic interventions are presently offered in 
managing neck pain with costs being considered as 
uncontrollable [8-31]. Consequently, the prevalence 
and disability in association with escalating costs 
secondary to spinal pain in general and neck pain in 
particular have become the focus of attention of the 
public-at-large, payer community, regulators, and 
finally, physicians and patients [3, 5-7, 32]. 
Neck pain may originate from intervertebral 
discs, facet joints, ligaments, fascia, muscles, and 
nerve root dura [11, 12]. The current evidence shows 
that the prevalence of cervical facet joint pain utilizing 
the criterion standard of ≥ 80% pain relief to range 
from 36% to 67% with controlled diagnostic blocks, 
with a false positive rate of 27% to 63% [11, 20]. 
Therapeutic cervical facet joint interventions have 
shown Level II evidence for cervical medial branch 
radiofrequency neurotomy and cervical therapeutic 
medial branch blocks with limited evidence for 
intraarticular injections with best evidence synthesis 
[12, 20]. Thus, there continue to be significant 
discussions surrounding various treatment modalities 
used in the management of chronic neck pain. 
Further, these discussions are exemplified by no 
demonstration of cost effectiveness or utility, 
increasing disability challenges, escalating utilization, 
diagnostic accuracy, and therapeutic effectiveness of 
various modalities [7, 11, 12, 20, 33-36]. Manchikanti et 
al. [8-10, 18] previously demonstrated that 
interventional techniques for chronic pain have 
increased dramatically from 2000 to 2014 with a 153% 
increase per 100,000 fee-for-service Medicare 
beneficiaries. Among these, cervical and thoracic facet 
joint injections increased 362.9%, and cervical and 
thoracic radiofrequency increased 911.5% from 2000 
to 2014, per 100,000 Medicare beneficiaries [8-10, 18].  
Even though multiple cost utility or effectiveness 
analysis studies and reviews have been published 
over the years in managing spinal pain [33, 35, 37-53], 
there are very few studies assessing the cost utility of 
non-surgical techniques in managing neck pain [39, 
40, 50-53]. Among the interventional techniques, there 
are none available for neck pain. However, there have 
been some studies providing cost utility analysis in 
managing low back and lower extremity pain. Among 
these, spinal cord stimulation was shown to be 
effective compared to conventional medical 
management at €5,624 per quality adjusted life years 
(QALY) [41]. Caudal epidural injections [47] were 
shown to be effective at a direct procedural cost of 
USD $2,173 per QALY in managing disc herniation, 
spinal stenosis, discogenic pain, or post surgery 
syndrome. In addition, percutaneous adhesiolysis [48] 
was demonstrated to be cost effective at a direct 
procedural cost of USD $2,650 QALY in recalcitrant 
post-surgery syndrome and spinal stenosis. Thus, the 
cost utility analysis does not provide the total cost. 
Highly regarded surgical literature from analysis of 
Spine Patient Outcomes Research Trial (SPORT) trial 
data [45, 46] has provided a basis for estimation of 
indirect cost, including drug therapy. These analyses 
showed overall cost effectiveness of disc herniation 
surgery [45] at USD $69,403 per QALY, whereas for 
spinal stenosis surgeries it was USD $77,600 per 
QALY and USD $115,600 per QALY for degenerative 
spondylolisthesis [46]. Further, these studies also 
showed direct costs without medication costs to be 
60% for spinal stenosis, 68% for disc herniation, and 
71% for degenerative spondylolisthesis with spinal 
stenosis with total costs of USD $26,222, $27,341, and 
$42,081, respectively. Based on these studies 
considering the direct procedural costs lowest at 60% 
and highest indirect costs of 40%, the cost utility of 
caudal epidural injections is estimated to be USD 
$3,628 and for percutaneous adhesiolysis, it is 
estimated to be USD $4,426 per QALY with 
multiplication of the costs by 1.67 [47, 48]. In addition, 
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cost utility analysis of lumbar interlaminar epidural 
injections in the treatment of lumbar disc herniation, 
central spinal stenosis, and axial or discogenic low 
back pain utilizing the extrapolate method of surgical 
interventions of direct cost, showed an average cost of 
USD $3,301 per QALY [49]. 
 The present investigation, therefore, was 
undertaken to produce pragmatic, reliable, overall 
cost utility information for therapeutic cervical medial 
branch blocks in managing chronic neck pain, with or 
without headache and upper extremity pain, based on 
a previously conducted double-blind, randomized, 
controlled trial with a 2-year follow-up [54, 55].  
Methods 
Study Design 
The current procedural cost utility analysis is 
based on a randomized controlled, double-blind trial 
of therapeutic cervical facet joint nerve blocks [54, 55]. 
Design and methodology of the trial were previously 
described [54, 55]. All patients in the trial had 
previously failed conservative treatment. After 
receiving 80% pain relief with controlled diagnostic 
blocks, they underwent therapeutic injections, either 
with or without steroids, in a contemporary 
interventional pain management setting in an 
ambulatory surgical center in the United States.  
Analysis 
The 120 patients in the trial, randomized into a 
group that received either local anesthetic or local 
anesthetic with steroids, were followed for 24 months 
(Fig. 1).  
Reimbursement rates as of 2016, for all patients 
from all carriers, are the basis of costs used for both 
facility and physician services, due to the 
ever-changing nature of costs [56, 57].  
 
 
Figure 1. Schematic presentation of patient flow at 2-year follow-up for therapeutic cervical facet joint nerve blocks [54, 55]. 
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Outcome Measures 
Outcomes were measured at post-treatment 3, 6, 
12, 18, and 24 months. Measurements included pain 
using the 11-point (0 - 10) numeric rating scale (NRS), 
the 0 - 50 Neck Disability Index (NDI), employment 
status, and opioids measured as morphine 
equivalents. Pain relief and disability improvement of 
50% were used as improvement measures.  
Cost Utility Analysis 
Procedural costs for 2 years were calculated 
using 2016 reimbursement data for both physician 
and facility expenses. Quality of life improvement per 
year (52 weeks) for 2 years (104 weeks) was estimated 
based on the costs of primary outcomes of significant 
pain relief and improvement in function of 50% of 
therapeutic cervical medial branch blocks [54, 55]. The 
derived procedural costs were considered as direct 
costs without costs of drugs, constituting 60% of the 
overall cost based on widely held surgical studies [45, 
46] and the remaining 40% was attributed to indirect 
costs. These costs were estimated from direct proce-
dural cost data with multiplication by a factor of 1.67. 
Extrapolation of the costs in this manuscript was 
based on the well-regarded cost utility analysis 
performed in surgical interventions of lumbar disc 
herniation, lumbar spinal stenosis, and lumbar 
spondylolisthesis from the SPORT trials [45, 46]. 
Tosteson et al. [45, 46] in detail describe their approach 
to calculation of direct and indirect costs, in which 
direct costs comprised medical and surgical costs, 
whereas indirect costs included productivity losses, 
missed days of housekeeping, and unpaid caregivers, 
etc. In our approach to extrapolation of these cost ratio 
analysis, we have also incorporated costs of 
medication into indirect costs. Based on this approach, 
with elimination of medication costs from direct costs, 
transferring them to indirect costs, the SPORT trials 
[45, 46] showed a 2-year cost of managing disc 
herniation of USD $18,645 (68%), with a total cost of 
USD $27,341. Similarly, for spinal stenosis and 
spondylolisthesis, direct costs without medication 
costs were estimated to be USD $15,717 with a total 
cost of USD $26,222 or USD $29,868 with total costs of 
USD $42,081 with 60% constituting for direct medical 
expenses without medication for spinal stenosis and 
71% apportioned to direct expense without 
medication for spondylolisthesis. Based on these 
expenses, Tosteson et al [45, 46] estimated QALY for 
disc herniation of USD $69,403 with 68% for direct 
medical costs without medical therapy, USD $77,600 
for spinal stenosis with direct medical costs of 60% 
and USD $115,600 per QALY for degenerative 
spondylolisthesis with direct medical costs of 71%. 
Consequently, in this analysis, costs were attributed 
as 40% to indirect expenses including medical therapy 
and 60% to direct costs without medical therapy, with 
multiplication by a factor of 1.67.  
The present investigation compared the 
unadjusted mean cost per patient. Incremental cost 
effectiveness analysis was not performed, as this was 
only one group. This was a comparative effectiveness 
trial with both groups yielding similar results. 
Results 
Patient Flow 
The 120 study patients receiving therapeutic 
medial branch blocks were grouped based on whether 
they received bupivacaine only or bupivacaine with 
steroids. In Group I, 90% were available for follow-up 
at 12 months; in Group II, it was 95%. At 24 months 
follow-up, 83% in Group I were available for 
follow-up; 88% in Group II (Fig. 1).  
Outcomes  
Baseline demographics and clinical 
characteristics are shown in Table 1. Total employed 
were 21 patients and total unemployed were 13 
patients combined in both groups. At the end of 24 
months, total unemployed was reduced to 2 (data not 
shown in the table). 
 
Table 1. Demographic characteristics and clinical characteristics of cervical therapeutic facet joint nerve blocks [54, 55]. 
  Group I 
(bupivacaine without steroid) 
(N = 60) 
Group II 
(bupivacaine with steroid) 
(N = 60) 
Pooled 
(N = 120) 
Gender Male 32% (19) 20% (12) 26% (31) 
 Female 68% (41) 80% (48) 74% (89) 
Age (years) Mean ± SD 45.7 + 13.2 42.6 + 14.1 44.1 + 13.7 
Height (inches) Mean ± SD 66.2 + 3.9 65.5 + 3.7 65.9 + 3.8 
Weight (lbs.) Mean ± SD 177.9 + 53.8 169.1 ± 40.8 173.5 + 47.8 
Duration of pain (months) Mean ± SD 120 + 122.2 87 + 104.0 103 + 114.2 
Mode of onset of pain  Gradual 57% (34) 57% (34) 57% (68) 
Sudden 11% (7) 11% (7) 12% (14) 
WC/MVA 32% (19) 32% (19) 31% (38) 
WC = Workers compensation, MVA = Motor vehicle injury 
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NRS and NDI data are shown in Table 2, 
showing baseline to 24-month improvement to be 
significant, but there was no significant difference 
with respect to the 2 groups against each other. Figure 
2 reveals that 70% of all patients had a significant 
reduction in the NRS and NDI at 24 months. 
 
Table 2. Pain relief and functional assessment evaluated by Neck 
Disability Index (NDI) characteristics with therapeutic cervical 
facet joint nerve blocks [54, 55]. 
Numeric Rating Score Group I Group II Pooled  
Baseline 8.2 ± 0.8 8.2 ± 1.1 8.2 ± 1.0 
6 months 3.6 ± 1.1 
(87%) 
3.5 ± 0.7 
(95%) 
3.4 ± 0.9 
(91%) 
12 months 3.7 ± 1.2 
(85%) 
3.4 ± 0.9 
(91%) 
3.6 ± 1.0 
(88%) 
24 months 3.5 ± 1.0 
(85%) 
3.2 ± 1.0 
(93%) 
3.3 ± 1.0 
(89%) 
Neck Disability Index    
Baseline 25.4 ± 5.9 25.1 ± 5.0 25.3 ± 5.5 
6 months 12.2 ± 5.9 
(78%) 
11.6 ± 4.2 
(88%) 
11.9 ± 5.1 
(83%) 
12 months 11.9 ± 5.4 
(85%) 
11.7 ± 4.5 
(85%) 
11.8 ± 5.0 
(85%) 
24 months 11.5 ± 5.1 
(85%) 
11.0 ± 4.7 
(90%) 
11.2 ± 4.9 
(87%) 
(____) illustrates proportion with significant pain relief (≥ 50%) from baseline  
 
Adverse Events 
Due to lack of adverse events reported among 
study participants in the investigation, no costs 
related to adverse events were incurred. 
Cost Utility Analysis 
In this analysis, cost for procedure, overall cost, 
and cost for improvement in quality of life were 
assessed based on the quality of life improvement as 
shown in Table 3. Average total cost per patient in 2 
years was also assessed.  
As shown in Table 3, total direct costs without 
medical therapy for 2 years were USD $4,222.08. The 
total direct costs for one year of improvement of 
quality of life were USD $2,551.65. Whereas, with 
extrapolation of indirect costs with the addition of 
40% costs, overall costs were estimated to be USD 
$4,261. 
Discussion 
The cost utility analysis of therapeutic cervical 
medial branch blocks in chronic persistent neck pain 
in patients who failed to respond to conservative 
management, with inclusion of 120 patients with a 
2-year follow-up showed QALY of USD $2,552 for 
direct procedural costs without inclusion of drug 
costs. The overall costs with direct and indirect costs 
were estimated to be USD $4,261 per QALY. Both 
groups of patients with or without steroids with 
bupivacaine showed similar results. There was 
significant improvement from baseline in the majority 
of patients. 
In this analysis, current reimbursement data of 
2016 was utilized from all carriers for all patients, 
related to changes in coverage policies and 
reimbursement payments and inflation [56, 57]. Due 
to multiple patients having undergone bilateral 
procedures and facet joint nerve blocks always 
involved at least 2 levels, average overall cost per 
patient was higher than in our previous cost utility 
studies of caudal epidural injections [47] and lumbar 
interlaminar epidural injections [49], but was similar 
or somewhat less than percutaneous adhesiolysis [48] 
of USD $3,628, USD $3,301 and USD $4,426, 
respectively. The only difference between the groups 
was there were no diagnostic blocks performed with 
caudal epidural injections. Diagnostic nerve blocks for 
cervical facet joint nerve blocks were not included in 
this analysis. Similarly, in percutaneous adhesiolysis 
in managing post lumbar surgery syndrome and 
lumbar central spinal stenosis, the prior cost of 
epidural injections or outcomes were also not 
included.  
 
 
Figure 2. Proportion of patients with significant reduction in Numeric Rating Score (NRS) and Neck Disability Index (NDI) (≥ 50% reduction from baseline) with 
therapeutic cervical facet joint nerve blocks. 
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Table 3. Analysis of cost effectiveness of cervical therapeutic medial branch nerve blocks in managing chronic pain (USD $). 
 Group I 
(bupivacaine without steroid) 
Group II 
(bupivacaine with steroid) 
Pooled 
Number of patients 60 60 120 
Total number of procedures for 2 years 342 344 686 
Number of treatments for 2 years per patient 
 (mean) ± SD 
5.7 ± 2.4 5.7 ± 2.1 5.7 ± 2.2 
Number of weeks with significant improvement  
for all patients in the study in weeks 
4999 5326 10325 
Significant improvement in two years per patient 
 (mean) ± SD 
83.3 ± 27.4 88.8 ± 21.1 86.0 ± 24.6 
Significant improvement in weeks per procedure  
(mean) ± SD 
15.0 ± 12.31 16.1 ± 14.1 15.6 ± 12.3 
Total Cost USD ($)    
Physician $66,652.26 $72,340.20 $138,992.46 
Facility $179,037.97 $188,619.19 $367,657.16 
Total $245,690.23 $260,959.38 $506,649.61 
Cost per procedure USD ($)    
Physician $194.89 $210.29 $202.61 
Facility $523.50 $548.31 $535.94 
Total $718.39 $758.60 $738.56 
Direct total costs per patient for two years USD ($) $4,094.84 $4,349.32 $4,222.08 
Direct procedural costs without medical therapy for 1-year improvement in 
quality of life USD ($) 
$2,555.69 $2,547.86 $2,551.65 
Indirect costs including drugs USD ($) for one-year improvement of life $1,712.31 $1,707.06 $1,709.60 
Total estimated cost USD ($) including procedural costs, drug costs, and indirect 
costs for one-year improvement in quality of life 
$4,268.00 $4,254.92 $4,261.25 
 
 
The purpose of cost utility analysis in health 
economics is to estimate the ratio between the cost of a 
health-related intervention and the benefit it produces 
in terms of number of years lived in full health by the 
beneficiaries. Therefore, it can be considered as a 
special case of cost effectiveness analysis, and both the 
terms are often used interchangeably. Consequently, 
in this scenario, cost is measured in monetary units, 
unlike cost-benefit analysis, in which benefits do not 
have to be expressed in monetary terms. Among the 
studies assessing cost effectiveness of various 
treatments in managing chronic neck pain [33, 35, 40, 
50-53], one study assessed [33] patient centered 
quality of life and health economics based on surgery 
for degenerative cervical myelopathy. A second study 
[35] evaluated the effect of obesity on cost per QALYs 
gained following anterior cervical discectomy and 
fusion in elective degenerative pathology. Witiw et al 
[33] showed mean QALY gained over the 24-month 
study period was 0.139 and the mean 2 years cost of 
treatment was Canadian (CAN) $19,217 ± CAN 
$12,404, with cost associated with operation 
comprising 65.7% of the total. They estimated lifetime 
incremental cost-to-utility ratios of surgical 
intervention of CAN $20,547 per QALY gained. 
Among the studies assessing nonsurgical treatments 
[40, 50, 51], Leininger et al. [50] showed that inflation 
adjusted costs of home exercise and advice with 
addition of spinal manipulative therapy would result 
in inflation adjusted to 2014 USD $65,731 per QALY 
gained. All other assessments showed improvements 
in the QALY, but without cost per QALY determined. 
Among earlier publications, Kepler et al [37] 
showed that one-year cost of QALY gained was less 
than USD $100,000 in only 45% of the studies 
assessed. Similarly, Indrakanti et al. [38] showed that a 
greater value was placed on studies of non-operative 
treatments compared to surgical treatments. Yet, in 
another systematic review, Dagenais et al. [39] showed 
highly variable costs for QALY ranging from USD 
$304 to USD $579,527, with a median cost of USD 
$13,000.  
Among the interventional techniques, Taylor et 
al. [41] illustrated the cost effectiveness for spinal cord 
stimulation based on NICE criteria [58] at a cost of 
£5,624 per QALY. In contrast, Kumar and Rizvi [43], 
in an assessment of cost effectiveness of spinal cord 
stimulation therapy in management of chronic pain of 
failed back surgery syndrome, complex regional pain 
syndrome, peripheral arterial disease, and refractory 
angina pectoris, showed 2010 CAN $9,293 CAN 
$11,216, CAN $9,350, and CAN $9,984 for failed back 
surgery syndrome, complex regional pain syndrome, 
peripheral arterial disease, and refractory angina 
pectoris, respectively, per QALY gained. Overall cost 
utility analysis of caudal epidural injections, lumbar 
interlaminar epidural injections, and percutaneous 
adhesiolysis yielded favorable results in managing 
chronic low back pain of various pathologies [45-49]. 
Manchikanti et al. [47] performed a cost utility 
analysis of caudal epidural injections in the treatment 
of lumbar disc herniation, axial or discogenic low 
back pain, central spinal stenosis, and post lumbar 
surgery syndrome showing average direct procedure 
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costs per one-year QALY of USD $2,173 and USD 
$3,628 of overall costs. Even though this study was 
limited to a single center, it included 480 patients in 
the analysis and data were derived from 4 separate 
randomized controlled trials (RCTs). Similarly, cost 
utility analysis of percutaneous adhesiolysis in 
managing pain of post lumbar surgery syndrome and 
lumbar central spinal stenosis was performed in a 
total of 130 patients after failure to response to caudal 
epidural injections from 2 RCTs from a single center 
showing direct procedural cost utility for one-year 
QALY of USD $2,650 and overall cost of USD $4,426 
[48]. Manchikanti et al. [47] performed a cost utility 
analysis of lumbar interlaminar epidural injections 
with or without steroids in the treatment of lumbar 
disc herniation, central spinal stenosis, and discogenic 
or axial low back pain with data derived from 3 RCTs 
[59-61] that included a 2-year follow-up, with 
inclusion of 360 patients in this analysis. The 
methodology described in this manuscript was 
utilized with multiplication of procedural costs 
without medical therapy by a factor of 1.67 with 
overall cost per QALY of USD $3,301 with direct costs 
of USD $1,977, somewhat less than caudal epidural 
injections and significantly less than cost utility of 
cervical therapeutic medial branch blocks in 
managing chronic neck pain described in this 
manuscript.  
Furlan et al. [40], in a systematic review and 
meta-analysis of efficacy, cost effectiveness, and safety 
of selected complementary and alternative medicine 
therapies for neck and low back pain, showed that 
alternative medicine treatments did not significantly 
reduce disability compared to sham, yielding mixed 
results. In this analysis, they included spinal 
manipulation in 2 studies assessing neck pain, 
massage in 3 studies, and acupuncture in one study. 
Acupuncture for neck pain was associated with 
significantly higher total cost compared to usual care 
(€1,565 vs. €1,496) with €12,469 per QALY gained in 
patients with chronic neck pain [52].  
Driessen et al. [51], in another systematic review 
of conservative treatments for neck pain and cost 
effectiveness, showed that only 5 economic 
evaluations met inclusion criteria. In their analysis, 
one study [53] comparing manual therapy plus advice 
and exercise compared to advice and exercise showed 
£34,000 per QALY threshold. Leininger et al. [50] 
showed cost effectiveness of spinal manipulative 
therapy, supervised exercise, and home exercise for 
older adults with chronic neck pain. They showed the 
inflation-adjusted cost in 2014 USD $65,731 per QALY 
gained, which was below the World Health 
Organization’s recommended threshold, based on 3 
times the 2014 per capita GDP of USD $163,889.  
Costs of surgical interventions are considered to 
be the highest in managing spinal pain [33, 35, 45, 46]. 
Cost effectiveness analysis of posterior cervical fusion 
in the cervical spine showed USD $20,547 per QALY 
in one study [34]; whereas, in another study [35], cost 
utility of anterior cervical discectomy and fusion in 
obese patients were USD $52,816 per QALY.  
Cost utility analysis has emerged over the years 
as an important tool in provision of value-based 
health care by merging patient-centered outcomes 
with utilization of health care resources [35, 59, 61, 
62-64]. A cost utility analysis is a type of cost 
effectiveness analysis that examines the costs and 
effectiveness of interventions by employing the QALY 
as its measure of effectiveness. Essentially, cost utility 
analysis examines the effects of interventions on both 
quantity and quality of life and are considered as the 
standard for reporting of cost effectiveness analysis 
and allow policymakers and providers to compare 
treatment strategies among different disciplines and 
identify the relative priorities for optimal resource 
allocation among various interventions [35, 43, 65, 66]. 
Numerous studies have analyzed the cost 
effectiveness of various cervical spine interventions 
[33, 35, 40, 50, 51, 52, 53, 67, 68]. A multitude of these 
analyses revealed highly variable costs for 
conservative management, as well as surgical 
management of cervical disorders. Consequently, the 
present assessment is the first assessment ever 
performed for interventional techniques in managing 
chronic neck pain, specifically with therapeutic facet 
joint nerve blocks.  
Indirect costs are generally not considered in 
health technology assessment [69-71]. In addition, 
based on the Affordable Care Act (ACA), cost 
effectiveness is not utilized as a basis for coverage or 
other analysis in the US [70-74]. However, cost 
effectiveness and cost utility analysis are frequently 
utilized as a basis for coverage in other countries 
including the United Kingdom [58]. These 
assessments are based on health technology 
assessment guidance. Despite the fact that the US 
does not openly consider cost utility analysis for 
coverage, the importance of high quality with low 
expense has been stressed with numerous public 
policy decisions including the ACA, physician quality 
reporting systems, value-based payment systems, 
merit-based incentive payment systems, and 
accountable interventional pain management [70-85].  
Multiple advantages of this study include the 
data derived from an RCT of 120 patients [54, 55] 
making it the first and only cost utility analysis from 
an RCT. In addition, it has been recommended that 
cost effectiveness models should make use of data on 
absolute pain including baseline pain, routinely 
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collected in trials, to inform model health-related 
quality of life outcomes [69]. Critchlow et al. [69] 
strongly recommended that absolute pain categories 
from 11-point NRS data are used to capture key pain 
outcomes. We also provided transparent data for all 
insurers for physician and operating room services. 
Further, this analysis also provides a pragmatic 
approach as it was performed in a practical, 
non-academic setting, despite utilizing strict 
parameters of diagnosis and therapy. Direct 
procedural cost utility analysis of USD $2,552 and 
overall costs of USD $4,261 per QALY is below the 
majority of modalities described thus far and well 
below the incremental cost effectiveness ratio of less 
than £20,000 per year QALY as recommended by 
NICE [58]. Consequently, the cervical medial branch 
blocks performed as described in this RCT meet the 
criteria for inclusion based on NICE criteria and cost 
utility analysis criteria in all countries. 
The limitations of this analysis are based on the 
fact that only current expenses in the therapeutic 
phase were included. In this regard, only physician 
and facility costs were utilized instead of analysis in 
various other settings, as well as other modalities 
utilized in conjunction with therapeutic facet joint 
nerve blocks (extrapolated with multiplication of a 
factor 1.67 of direct procedural costs), as well as the 
cost of the diagnostic nerve blocks. However, the 
benefits of returning to work, also have not been 
analyzed.  
Utilization of diagnostic blocks also may 
increase the cost for 2 procedures at a cost of USD 
$740 to USD $1,550 for each patient, but with addition 
of 9 to 10 weeks of significant improvement, which 
may reduce one procedure, thus adding less than 
USD $500 per QALY. In addition, use of payments 
from 2016 may also be criticized; however, it is 
essential to use the current and realistic payment rates 
based on dynamic changes in payment policies. In 
fact, there have been significant reductions in 
Medicare payments and those by other carriers in 
2017. Consequently, utilizing 2017 data may even 
further reduce the cost of the procedures performed. 
Overall, the cost utility analysis of this 
assessment based on the reimbursement for physician 
and facility charges in an ambulatory surgery center 
in a contemporary interventional pain management 
setting, utilizing the current data, may not apply to all 
settings. Further, all the patients underwent 80% pain 
relief as the criterion standard for inclusion in the 
therapeutic phase. It may be argued that 
radiofrequency neurotomy may be more cost effective 
since it provides longer-term relief [12, 13, 20]; 
however, there have not been any cost estimations 
available for cervical radiofrequency neurotomy. 
Further, with expected improvement with 
radiofrequency of 6 months with a single treatment, 
and twice the costs of procedures, costs may be 
similar. However, as many patients presented with 
bilateral pain requiring bilateral therapeutic facet joint 
nerve blocks incorporated into this cost utility 
analysis, twice the number of procedures may be 
required with radiofrequency neurotomy as 
procedures are performed only on one side, 
increasing the potential costs and reducing cost utility 
value.  
These costs are only applicable for procedures 
performed in an ambulatory surgery setting with 
sterile operating room [56, 57]. Consequently, it is 
estimated that costs of this analysis overall may be 
approximately 30% to 70% higher in a hospital setting 
and approximately 20% to 30% lower compared to an 
in-office setting [56, 57].  
Conclusion 
In the present investigation, the cost utility 
analysis of therapeutic facet joint nerve blocks in the 
treatment of chronic recalcitrant neck pain with or 
without headache and upper extremity pain shows 
cost utility of direct procedural cost of USD $2,552 per 
QALY and overall cost utility of USD $4,261 per 
QALY. 
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